期刊文献+

Efficacy and safety of transnasal butorphanol for pain relief after anal surgery 被引量:13

Efficacy and safety of transnasal butorphanol for pain relief after anal surgery
下载PDF
导出
摘要 AIM:To compare the analgesic properties and efficacy of transnasal butorphanol with intramuscular meperidine after anal surgery.METHODS: Sixty patients who underwent fistulectomy were enrolled in the study from January 2006 to December 2007. They were randomly divided into transnasal butorphanol (n=30) or intramuscular meperidine (n=30) treatment groups. Assessment of postoperative pain was made using a visual analogue scale (VAS). The VAS score was recorded 6 h after the completion of surgery, before receiving the first dose of analgesic, 60 min after analgesia and the next morning. Any adverse clinical effects such as somnolence, dizziness, nausea or vomiting were recorded. Satisfaction with narcotic efficacy, desire to use the particular analgesic in the future and any complaints were recorded by patients using questionnaires before being discharged.RESULTS: Forty-two men and eighteen women were included in the study. There were no significant differences in VAS scores between the groups within 24 h. Length of hospital stay and the incidence of adverse effects between the groups were similar. In addition, most patients were satisfied with butorphanol nasal spray and wished to receive this analgesic in the future, if needed.CONCLUSION: Butorphanol nasal spray is effective for the relief of pain after fistulectomy. However, it offered patients more convenient usage and would be suitable for outpatients. AIM: To compare the analgesic properties and efficacy of transnasal butorphanol with intramuscular meperidine after anal surgery. METHODS: Sixty patients who underwent fistulectomy were enrolled in the study from January 2006 to December 2007. They were randomly divided into transnasal butorphanol (n = 30) or intramuscular meperidine (n = 30) treatment groups. Assessment of postoperative pain was made using a visual analogue scale (VAS). The VAS score was recorded 6 h after the completion of surgery, before receiving the first dose of analgesic, 60 min after analgesia and the next morning. Any adverse clinical effects such as somnolence, dizziness, nausea or vomiting were recorded. Satisfaction with narcotic efficacy, desire to use the particular analgesic in the future and any complaints were recorded by patients using questionnaires before being discharged. RESULTS: Forty-two men and eighteen women were included in the study. There were no significant differences in VAS scores between the groups within 24 h. Length of hospital stay and the incidence of adverse effects between the groups were similar. In addition, most patients were satisfied with butorphanol nasal spray and wished to receive this analgesic in the future, if needed. CONCLUSION: Butorphanol nasal spray is effective for the relief of pain after fistulectomy. However, it offered patients more convenient usage and would be suitable for outpatients.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第38期4829-4832,共4页 世界胃肠病学杂志(英文版)
关键词 BUTORPHANOL FISTULECTOMY MEPERIDINE OPIOID 手术 肛门 止痛 疗效 镇痛作用 安全 VAS
  • 相关文献

参考文献13

  • 1Gillis JC, Benfield P, Goa KL. Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 1995; 50:157-175.
  • 2Vandam LD. Drug therapy: butorphanol. N Engl J Med 1980; 302:381-384.
  • 3Scott JL, Smith MS, Sanford SM, Shesser RF, Rosenthal RE, Smith JP, Feied CF, Ghezzi KT, Hunt DM. Effectiveness of transnasal butorphanol for the treatment of musculoskeletal pain. Am J Emerg Med 1994; 12:469471.
  • 4Dale o, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002; 46:759-770.
  • 5Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman NJ 3rd, Saper JR, Solomon S. Transnasal butorphanol in the treatment of acute migraine. Headache 1995; 35:65-69.
  • 6Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs 2004; 18:671-685.
  • 7Ladov MJ, Precheur HV, Rauch DM, Engel PS, Stern RK. An open-label evaluation of the efficacy and safety of Stadol NS with ibuprofen in the treatment of pain after removal of impacted wisdom teeth. J Oral Maxillofac Surg 2000; 58: 15-18.
  • 8Wermeling DP, Grant GM, Lee A, Alexander N, Rudy AC. Analgesic effects of intranasal butorphanol tartrate administered via a unit-dose device in the dental impaction pain model: a randomized, double-blind, placebo- controlled, parallel-group study. Clin Ther 2005; 27:430-440.
  • 9Olsen JC, McGrath NA, Schwarz DG, Cutcliffe BJ, Stern JL. A double-blind randomized clinical trial evaluating the analgesic efficacy of ketorolac versus butorphanol for patients with suspected biliary colic in the emergency department. Acad Emerg Med 2008; 15:718-722.
  • 10Abboud TK, Zhu J, Gangolly 1, Longhitano M, Swart F, Makar A, Chu G, Cool M, Mantilla M, Kurtz N. Transnasal butorphanol: a new method for pain relief in post-cesarean section pain. Acta Anaesthesiol Scand 1991; 35:14-18.

同被引文献61

引证文献13

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部